VERTEX PHARMACEUTICALS INC / MA — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$15
Book Value Per Share
$72
Free Cash Flow Per Share
$12
Cash Per Share
$20
Revenue Per Share
$47
OCF Per Share
$14
Return on Equity
22.5%
Return on Assets
16.4%
Return on Invested Capital
20.3%
Current Ratio
2.90
Quick Ratio
2.46
Asset Turnover
0.50
Days Sales Outstanding
62.43
Days Payables Outstanding
102.05
Days Inventory On Hand
372.85
Cash Conversion Cycle
333.23
R&D / Revenue
32.6%
SBC / Revenue
5.7%
Capex / Revenue
3.6%
Working Capital
$7.34B
Net Current Asset Value
$4.22B
Invested Capital
$18.67B
OCF / Net Income
0.92
FCF / Net Income
0.81
Accruals Ratio (Sloan)
1.3%
Net Debt
$-6.61B
Net Debt / EBITDA
-1.51
Interest Coverage
313.78
Cash Coverage
273.04
Capex Coverage
8.30
Tangible Common Equity
$17.15B
TCE / Total Assets
66.9%
Goodwill / Total Assets
4.2%
NOPAT
$3.55B
Cash ROIC
18.2%
WC / Revenue
61.2%
Capex / D&A
2.09
Reinvestment Rate
5.5%
Total Payout Ratio
51.0%
Asset Growth vs Revenue Growth
4.9%
Revenue 5Y CAGR
14.1%
EPS 5Y CAGR
7.8%
FCF 5Y CAGR
1.3%
EBITDA 5Y CAGR
8.1%
Book Value 5Y CAGR
16.5%
Stock Price (FY-end)
$453
Market Cap
$116.97B
P/E Ratio
29.59
P/S Ratio
9.75
P/B Ratio
6.27
P/TB Ratio
6.82
P/OCF Ratio
32.21
P/FCF Ratio
36.62
Enterprise Value
$110.36B
EV / EBITDA
25.18
EV / Sales
9.20
EV / FCF
34.55
FCF Yield
2.7%
Shareholder Yield
1.1%
Buyback Yield
1.7%
R&D Yield
3.3%
Capex Yield
0.4%
Operating Leverage
0.41
Graham Number
$158
Shares Variation (YoY)
0.0%
Beta (5Y)
0.57
Cost of Equity
7.3%
52W High
$514
52W Low
$367
Trailing Return 1Y
10.9%
Trailing Return 5Y
92.2%
F-Score (Piotroski)
5.00
Z-Score (Altman)
12.15
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.